To address the need for efficient RNA delivery beyond the liver, my lab designs inhalable, biocompatible nanocarriers for siRNA delivery to the lung. While siRNA drugs typically target the liver, the lung presents undruggable targets that RNA therapeutics could address. Nebulizable nanocarriers for pulmonary RNA administration can extend delivery beyond the liver. siRNA therapeutics are encapsulated in lipid nanoparticles (LNPs) or administered as GalNac-conjugates to protect RNA and facilitate membrane delivery. However, approved LNPs pose immunogenic risks, primarily target the liver, and offer low drug loading. Additionally, lipid-based carriers lack stability in lung surfactant and under nebulization stresses. To overcome these issues, we design polymer-based siRNA formulations.

Moderator: - Mathew Cherian, Consultant, USA

Co-moderator: - Nikolina Biskic, Regulatory Affairs Manager, Switzerland

Panellists: - Olivia Merkel, Professor of Drug Delivery Ludwig Maxmillian University (LMU), Munich, Germany